Conclusion
At present, there is no consensus or published guidelines on ECMO management in the sickle cell patient population; hence, there are no recommendations for this patient population with SARS-CoV-2 infection. With no immediate end in sight for the ongoing pandemic, any new information that can shed a light on clinical management of sickle cell patients with SARS-CoV-2 infection is greatly needed. Despite having SCD and SARS-CoV-2, our patient was supported on VV-ECMO for 71 days with a favorable outcome and without thrombosis, bleeding, pulmonary hypertension, end organ dysfunction, or sepsis as a bridge to recovery through a comprehensive multidisciplinary team effort.